Haben selektive COX-2-Hemmer unerwünschte renale und kardiovaskuläre Wirkungen [Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?].

Details

Serval ID
serval:BIB_5BF09D2EFD14
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Haben selektive COX-2-Hemmer unerwünschte renale und kardiovaskuläre Wirkungen [Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?].
Journal
Praxis
Author(s)
Mathieu C., Meier P., Meyer zu Starten A., Burnier M.
ISSN
1661-8157 (Print)
ISSN-L
1661-8157
Publication state
Published
Issued date
2005
Volume
94
Number
47
Pages
1851-1858
Language
german
Notes
Publication types: English Abstract ; Journal Article ; Review
Abstract
Selective cyclooxygenase-2-inhibitors (COX-2) were developed as an alternative to the non-steroidal anti-inflammatory drugs (NSAID) in order to reduce their known gastrointestinal and renal toxicity. Several recent studies have shown the complex mechanism of the cyclooxygenase-2. The inhibition of the COX-2 has effects on renal hemodynamics, renal salt and water retention and may increase the thromboembolic and therefore the cardiovascular risk. The renal toxicity of the COX-2 inhibitors is similar to that of traditional NSAID. Regarding these data, COX-2 inhibitors should be prescribed with much caution to high risk patients, that is, patients with renal failure and/or cardiovascular diseases.
Keywords
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage, Anti-Inflammatory Agents, Non-Steroidal/toxicity, Cardiovascular Diseases/chemically induced, Cardiovascular Diseases/mortality, Cyclooxygenase 2 Inhibitors/administration & dosage, Cyclooxygenase 2 Inhibitors/toxicity, Dose-Response Relationship, Drug, Humans, Kidney Diseases/chemically induced, Kidney Diseases/mortality, Naproxen/administration & dosage, Naproxen/toxicity, Pyrazoles/administration & dosage, Pyrazoles/toxicity, Risk Assessment, Sulfonamides/administration & dosage, Sulfonamides/toxicity, Thromboembolism/chemically induced, Thromboembolism/mortality
Pubmed
Create date
06/09/2011 10:44
Last modification date
20/08/2019 14:14
Usage data